

PHARMACY POLICY STATEMENT

BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Nocdurna is a vasopressin analog initially approved by the FDA in 2018. It is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. Nocturnal polyuria is the most frequent cause of nocturia, having been shown in studies to be responsible for up to 88% of cases. It is thought to result from an abnormality of the circadian rhythm of



- d) Renal impairment with an estimated glomerular filtration rate (eGFR) below 50 mL/min/1.73 m²;
- e) Gastroenteritis, salt-wasting nephropathies, or acute systemic infection;
- f) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion.
- 8. Females: 27.7 mcg once daily one hour before bedtime, Males: 55.3 mcg once daily one hour before bedtime. Quantity limit: 30 sublingual tablets per 30 days.

If all the above requirements are met, the medication will be approved for 3 months.

- 1. Chart notes must show improvement or stabilized signs and symptoms of condition, demonstrated by reduction in nocturnal voids.
- 2. Member has normal serum sodium concentrations labs submitted with chart notes.

If all the above requirements are met, the medication will be approved for an additional 12 months.

Reduction of evening intake of diuretic fluids, such as alcohol, coffee, tea and liquids with artificial sweeteners

Avoiding use of nighttime diuretics

Treatment of peripheral edema by use of compression stockings or evening elevation of the legs Emptying the bladder prior to bedtime

Weight reduction

New policy for Nocdurna created.

References:

- 1. Nocdurna [package insert] Parsippany, NJ: Ferring; November 2020
- 2. Weiss JP, Everaert K. Management of nocturia and nocturnal polyuria. Urology. 2019;133S:24-33.
- 3. Mathias O, et al. A practical approach to the management of nocturia. Int J Clin Pract. 2017. 71(11):e13027.

Effective date: 10/01/2022 Revised date: 04/21/2022